{"pmid":32382259,"pmcid":"PMC7201058","title":"Recommendations for a safety dental care management during SARS-CoV-2 pandemic.","text":["Recommendations for a safety dental care management during SARS-CoV-2 pandemic.","As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted mainly through droplets, sneezes and aerosols, there is a high risk of transmission during dental procedures. This report describes measures that can be adopted by oral healthcare personnel to minimize the risk of cross-contamination in clinical practice during the current SARS-CoV-2 pandemic.","Rev Panam Salud Publica","Martins-Filho, Paulo Ricardo","de Gois-Santos, Vanessa Tavares","Tavares, Carolina Santos Souza","de Melo, Elisama Gomes Magalhaes","do Nascimento-Junior, Edmundo Marques","Santos, Victor Santana","32382259"],"abstract":["As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted mainly through droplets, sneezes and aerosols, there is a high risk of transmission during dental procedures. This report describes measures that can be adopted by oral healthcare personnel to minimize the risk of cross-contamination in clinical practice during the current SARS-CoV-2 pandemic."],"journal":"Rev Panam Salud Publica","authors":["Martins-Filho, Paulo Ricardo","de Gois-Santos, Vanessa Tavares","Tavares, Carolina Santos Souza","de Melo, Elisama Gomes Magalhaes","do Nascimento-Junior, Edmundo Marques","Santos, Victor Santana"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32382259","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.26633/RPSP.2020.51","keywords":["coronavirus infection","sars virus","dental care","pandemics","pneumonia, viral","virus diseases"],"topics":["Prevention"],"weight":1,"_version_":1666267276767133696,"score":9.490897,"similar":[{"pmid":32454806,"pmcid":"PMC7241577","title":"Comparing South Korea and Italy's healthcare systems and initiatives to combat COVID-19.","text":["Comparing South Korea and Italy's healthcare systems and initiatives to combat COVID-19.","Italy and South Korea have two distinctly different healthcare systems, causing them to respond to public health crises such as the COVID-19 pandemic in markedly different ways. Differences exist in medical education for both countries, allowing South Korean medical graduates to have a more holistic education in comparison to their Italian counterparts, who specialize in medical education earlier on. Additionally, there are fewer South Korean physicians per 1000 people in South Korea compared to Italian physicians per 1000 people in Italy. However, both countries have a national healthcare system with universal healthcare coverage. Despite this underlying similarity, the two countries addressed COVID-19 in nearly opposite manners. South Korea employed technology and the holistic education of its physician community, despite having a smaller proportion of physicians in society, to its advantage by implementing efficacious drive-through centers that test suspected individuals rapidly and with little to no contact with healthcare staff, decreasing the possibility of transmission of COVID-19. Conversely, Italy is presently considered the epicenter of the outbreak in Europe and has recorded the highest death toll of any country outside of mainland China. This is partially due to the reactionary nature of Italy's public health measures compared to South Korea's proactive response. The different healthcare responses of South Korea and Italy can inform decisions made by public health bodies in other countries, especially in countries across the Americas, which can selectively adopt policies that have worked in curtailing the spread of COVID-19 and learn from mistakes made by both countries.","Rev Panam Salud Publica","Palaniappan, Ashwin","Dave, Udit","Gosine, Brandon","32454806"],"abstract":["Italy and South Korea have two distinctly different healthcare systems, causing them to respond to public health crises such as the COVID-19 pandemic in markedly different ways. Differences exist in medical education for both countries, allowing South Korean medical graduates to have a more holistic education in comparison to their Italian counterparts, who specialize in medical education earlier on. Additionally, there are fewer South Korean physicians per 1000 people in South Korea compared to Italian physicians per 1000 people in Italy. However, both countries have a national healthcare system with universal healthcare coverage. Despite this underlying similarity, the two countries addressed COVID-19 in nearly opposite manners. South Korea employed technology and the holistic education of its physician community, despite having a smaller proportion of physicians in society, to its advantage by implementing efficacious drive-through centers that test suspected individuals rapidly and with little to no contact with healthcare staff, decreasing the possibility of transmission of COVID-19. Conversely, Italy is presently considered the epicenter of the outbreak in Europe and has recorded the highest death toll of any country outside of mainland China. This is partially due to the reactionary nature of Italy's public health measures compared to South Korea's proactive response. The different healthcare responses of South Korea and Italy can inform decisions made by public health bodies in other countries, especially in countries across the Americas, which can selectively adopt policies that have worked in curtailing the spread of COVID-19 and learn from mistakes made by both countries."],"journal":"Rev Panam Salud Publica","authors":["Palaniappan, Ashwin","Dave, Udit","Gosine, Brandon"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454806","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.26633/RPSP.2020.53","keywords":["coronavirus infection","sars virus","health systems","pandemics","pneumonia, viral","virus diseases"],"locations":["Italy","South Korea","South Korean","Italian","South Korean","South Korea","Italian","Italy","South Korea","Italy","China","Italy","South Korea's","South Korea","Italy","South Korea","Italy"],"countries":["Korea, Republic of","Italy","China"],"countries_codes":["KOR|Korea, Republic of","ITA|Italy","CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1667881798403620864,"score":211.50249},{"pmid":32454808,"pmcid":"PMC7241574","title":"To breastfeed or not to breastfeed? Lack of evidence on the presence of SARS-CoV-2 in breastmilk of pregnant women with COVID-19.","text":["To breastfeed or not to breastfeed? Lack of evidence on the presence of SARS-CoV-2 in breastmilk of pregnant women with COVID-19.","A rapid systematic review was carried out to evaluate the current evidence related to the presence of SARS-CoV-2 in breast milk from pregnant women with COVID-19. Eight studies analyzing the presence of SARS-CoV-2 RNA in the breast milk of 24 pregnant women with COVID-19 during the third trimester of pregnancy were found. All patients had fever and/or symptoms of acute respiratory illness and chest computed tomography images indicative of COVID-19 pneumonia. Most pregnant women had cesarean delivery (91.7%) and two neonates had low birthweight (< 2 500 g). Biological samples collected immediately after birth from upper respiratory tract (throat or nasopharyngeal) of neonates and placental tissues showed negative results for the presence SARS-CoV-2 by RT-PCR test. No breast milk samples were positive for SARS-CoV-2 and, to date, there is no evidence on the presence of SARS-CoV-2 in breast milk of pregnant women with COVID-19. However, data are still limited and breastfeeding of women with COVID-19 remains a controversial issue. There are no restrictions on the use of milk from a human breast milk bank.","Rev Panam Salud Publica","Martins-Filho, Paulo Ricardo","Santos, Victor Santana","Santos, Hudson P Jr","32454808"],"abstract":["A rapid systematic review was carried out to evaluate the current evidence related to the presence of SARS-CoV-2 in breast milk from pregnant women with COVID-19. Eight studies analyzing the presence of SARS-CoV-2 RNA in the breast milk of 24 pregnant women with COVID-19 during the third trimester of pregnancy were found. All patients had fever and/or symptoms of acute respiratory illness and chest computed tomography images indicative of COVID-19 pneumonia. Most pregnant women had cesarean delivery (91.7%) and two neonates had low birthweight (< 2 500 g). Biological samples collected immediately after birth from upper respiratory tract (throat or nasopharyngeal) of neonates and placental tissues showed negative results for the presence SARS-CoV-2 by RT-PCR test. No breast milk samples were positive for SARS-CoV-2 and, to date, there is no evidence on the presence of SARS-CoV-2 in breast milk of pregnant women with COVID-19. However, data are still limited and breastfeeding of women with COVID-19 remains a controversial issue. There are no restrictions on the use of milk from a human breast milk bank."],"journal":"Rev Panam Salud Publica","authors":["Martins-Filho, Paulo Ricardo","Santos, Victor Santana","Santos, Hudson P Jr"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454808","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.26633/RPSP.2020.59","keywords":["coronavirus infection","sars virus","breast feeding","pandemics","pneumonia, viral","virus diseases"],"topics":["Diagnosis"],"weight":1,"_version_":1667983494513426432,"score":206.28322},{"pmid":32487985,"title":"[Delivery of oral health in andalusian health service on the de-escalation of SARS-CoV-2].","text":["[Delivery of oral health in andalusian health service on the de-escalation of SARS-CoV-2].","The pandemic declared by SARS-CoV-2 has meant a crisis in the health system that forced the urgent implementation of preventive public health measures. The respiratory transmission virus remains stable on surfaces, being able to spread by air in respiratory droplets or in procedures that generate aerosols. Dental activity is one of the professional sectors with the highest exposure index, both due to the generation of aerosols in most interventions, as well as the impossibility of maintaining a safe distance between patients and professionals. The postponement of scheduled and non-urgent healthcare activities in dental offices is one of the measures implemented to reduce the risk that it posed for the health and well-being of citizens. This report addresses the recommendations and measures to be taken into account to minimize risks in the Oral Health Units of the Andalusian Public Health System, to address the oral pathology of the population assigned in the scenario of improvement of the pandemic and its partial lack of confinement.","Rev Esp Salud Publica","Exposito Delgado, Antonio","Visuerte Sanchez, Jose Manuel","Soto Ibarreta, Maria Teresa","Hernandez Nieto, Josefina","Cervino Ferradanes, Santiago","32487985"],"abstract":["The pandemic declared by SARS-CoV-2 has meant a crisis in the health system that forced the urgent implementation of preventive public health measures. The respiratory transmission virus remains stable on surfaces, being able to spread by air in respiratory droplets or in procedures that generate aerosols. Dental activity is one of the professional sectors with the highest exposure index, both due to the generation of aerosols in most interventions, as well as the impossibility of maintaining a safe distance between patients and professionals. The postponement of scheduled and non-urgent healthcare activities in dental offices is one of the measures implemented to reduce the risk that it posed for the health and well-being of citizens. This report addresses the recommendations and measures to be taken into account to minimize risks in the Oral Health Units of the Andalusian Public Health System, to address the oral pathology of the population assigned in the scenario of improvement of the pandemic and its partial lack of confinement."],"journal":"Rev Esp Salud Publica","authors":["Exposito Delgado, Antonio","Visuerte Sanchez, Jose Manuel","Soto Ibarreta, Maria Teresa","Hernandez Nieto, Josefina","Cervino Ferradanes, Santiago"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32487985","source":"PubMed","week":"202023|Jun 01 - Jun 07","keywords":["dental care","dental health services","infection control","prevention","spain","virology"],"locations":["andalusian"],"topics":["Prevention"],"weight":1,"_version_":1668623433640968194,"score":173.79398},{"pmid":32454807,"pmcid":"PMC7241573","title":"COVID-19 and newborn health: systematic review.","text":["COVID-19 and newborn health: systematic review.","Objective: To describe perinatal and neonatal outcomes in newborns exposed to SARS-CoV-2. Methods: A systematic review was conducted by searching PubMed Central, LILACS, and Google Scholar using the keywords 'covid ' AND 'newborn' OR 'child' OR 'infant,' on 18 March 2020, and again on 17 April 2020. One researcher conducted the search and extracted data on demographics, maternal outcomes, diagnostic tests, imaging, and neonatal outcomes. Results: Of 256 publications identified, 20 met inclusion criteria and comprised neonatal outcome data for 222 newborns whose mothers were suspected or confirmed to be SARS-CoV-2 positive perinatally (17 studies) or of newborns referred to hospital with infection/pneumonia (3 studies). Most (12 studies) were case-series reports; all were from China, except three (Australia, Iran, and Spain). Of the 222 newborns, 13 were reported as positive for SARS-CoV-2; most of the studies reported no or mild symptoms and no adverse perinatal outcomes. Two papers among those from newborns who tested positive reported moderate or severe clinical characteristics. Five studies using data on umbilical cord blood, placenta, and/or amniotic fluid reported no positive results. Nine studies reported radiographic imaging, including 5 with images of pneumonia, increased lung marking, thickened texture, or high-density nodular shadow. Minor, non-specific changes in biochemical variables were reported. Studies that tested breast milk reported negative SARS-CoV-2 results. Conclusions: Given the paucity of studies at this time, vertical transmission cannot be confirmed or denied. Current literature does not support abstaining from breastfeeding nor separating mothers and newborns. Further evidence and data collection networks, particularly in the Americas, are needed for establishing definitive guidelines and recommendations.","Rev Panam Salud Publica","Duran, Pablo","Berman, Stephen","Niermeyer, Susan","Jaenisch, Thomas","Forster, Thais","Gomez Ponce de Leon, Rodolfo","De Mucio, Bremen","Serruya, Suzanne","32454807"],"abstract":["Objective: To describe perinatal and neonatal outcomes in newborns exposed to SARS-CoV-2. Methods: A systematic review was conducted by searching PubMed Central, LILACS, and Google Scholar using the keywords 'covid ' AND 'newborn' OR 'child' OR 'infant,' on 18 March 2020, and again on 17 April 2020. One researcher conducted the search and extracted data on demographics, maternal outcomes, diagnostic tests, imaging, and neonatal outcomes. Results: Of 256 publications identified, 20 met inclusion criteria and comprised neonatal outcome data for 222 newborns whose mothers were suspected or confirmed to be SARS-CoV-2 positive perinatally (17 studies) or of newborns referred to hospital with infection/pneumonia (3 studies). Most (12 studies) were case-series reports; all were from China, except three (Australia, Iran, and Spain). Of the 222 newborns, 13 were reported as positive for SARS-CoV-2; most of the studies reported no or mild symptoms and no adverse perinatal outcomes. Two papers among those from newborns who tested positive reported moderate or severe clinical characteristics. Five studies using data on umbilical cord blood, placenta, and/or amniotic fluid reported no positive results. Nine studies reported radiographic imaging, including 5 with images of pneumonia, increased lung marking, thickened texture, or high-density nodular shadow. Minor, non-specific changes in biochemical variables were reported. Studies that tested breast milk reported negative SARS-CoV-2 results. Conclusions: Given the paucity of studies at this time, vertical transmission cannot be confirmed or denied. Current literature does not support abstaining from breastfeeding nor separating mothers and newborns. Further evidence and data collection networks, particularly in the Americas, are needed for establishing definitive guidelines and recommendations."],"journal":"Rev Panam Salud Publica","authors":["Duran, Pablo","Berman, Stephen","Niermeyer, Susan","Jaenisch, Thomas","Forster, Thais","Gomez Ponce de Leon, Rodolfo","De Mucio, Bremen","Serruya, Suzanne"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454807","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.26633/RPSP.2020.54","keywords":["coronavirus infection","sars virus","congenital, hereditary, and neonatal diseases and abnormalities","infectious disease transmission, vertical","pandemics","virus diseases"],"locations":["China","Australia","Iran","Spain","placenta"],"countries":["China","Iran, Islamic Republic of","Spain","Australia"],"countries_codes":["CHN|China","IRN|Iran, Islamic Republic of","ESP|Spain","AUS|Australia"],"topics":["Diagnosis","Transmission"],"weight":1,"_version_":1667881798407815168,"score":170.36285},{"pmid":32256547,"pmcid":"PMC7105280","title":"Clinical trials on drug repositioning for COVID-19 treatment.","text":["Clinical trials on drug repositioning for COVID-19 treatment.","The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.","Rev Panam Salud Publica","Rosa, Sandro G Viveiros","Santos, Wilson C","32256547"],"abstract":["The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution."],"journal":"Rev Panam Salud Publica","authors":["Rosa, Sandro G Viveiros","Santos, Wilson C"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32256547","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.26633/RPSP.2020.40","keywords":["drug repositioning","clinical trials as topic","coronavirus infection","pandemics","pneumonia, viral","virus diseases"],"locations":["Wuhan","Hubei","China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine","remdesivir","Oseltamivir","Chloroquine","Lopinavir","Bevacizumab","Ritonavir","Methylprednisolone","favipiravir","arbidol"],"topics":["Treatment"],"weight":1,"_version_":1666138493088169984,"score":157.11229}]}